Patient trial validates Ebola rapid test

A 15-minute, on-the-spot blood test for Ebola was as accurate in a patient trial as the most widely-used laboratory-based test, its US-based developers said today.
An affordable, rapid diagnostic test would be an invaluable tool for health workers on the ground, allowing them to quickly identify and isolate infected individuals and curtail the spread of the deadly haemorrhagic virus.
Dubbed ReEBOV, the kit manufactured by Colorado-based Corgenix, works with a drop of blood from a finger prick and a test strip that changes colour in five to 15 minutes.
It requires very little training to use, but one potential drawback is that it needs refrigeration.

The standard test in use today, RealStar RT-PCR, requires analysis of much larger blood samples at a laboratory with a high biosafety level and trained staff -- facilities often not within easy reach of outbreak zones.
Manufactured by German company altona Diagnostics, RealStar also poses risks to those who collect, transport and test the samples.

"Laboratory results can sometimes take days to return," said a press statement issued by The Lancet medical journal, which published the study results.
"Delays like this result not only in the failure to diagnose and treat Ebola-infected patients, but also in individuals without Ebola being admitted to holding units where they may be subsequently infected with the virus," it quoted the study's senior author Nira Pollock, of the Boston Children's Hospital, as saying.

For the trial, Pollock and a team used both the ReEBOV rapid test and RealStar on 105 suspected Ebola patients in February this year at two government-run treatment centres in Sierra Leone -- one of three countries hardest hit by the current outbreak.
ReEBOV detected all 28 Ebola cases diagnosed by RealStar -- a 100-percent level of sensitivity, but much, much faster.
From this, "we can conclude that the ReEBOV rapid diagnostic test could be very useful as a rapid test for Ebola virus disease at the point of care in high-risk populations," the study said.
But the research also revealed some disconcerting data concerning the reliability of the benchmark test, RealStar, itself.

Six of the 77 RealStar-negative cases tested positive with ReEBOV. And further checks with an alternative RealStar-like test called Trombley, not yet in wide use, revealed a handful of cases with low virus levels that had been missed by both the others.